Composite three-marker assay for early detection of kidney cancer

Dong Su Kim, Young Deuk Choi, Mihyang Moon, Suki Kang, Jong Baeck Lim, Kyung Min Kim, Kyung Mok Park, Nam Hoon Cho

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.

Original languageEnglish
Pages (from-to)390-398
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume22
Issue number3
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Nicotinamide N-Methyltransferase
Kidney Neoplasms
Early Detection of Cancer
Biomarkers
Kidney
Control Groups
Tumor Biomarkers
Renal Cell Carcinoma
Neoplasms
Research Design

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Kim, Dong Su ; Choi, Young Deuk ; Moon, Mihyang ; Kang, Suki ; Lim, Jong Baeck ; Kim, Kyung Min ; Park, Kyung Mok ; Cho, Nam Hoon. / Composite three-marker assay for early detection of kidney cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2013 ; Vol. 22, No. 3. pp. 390-398.
@article{83c71d3c435749fcaa295f6dd573e355,
title = "Composite three-marker assay for early detection of kidney cancer",
abstract = "Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90{\%} specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9{\%} and 95.7{\%}, respectively. The predictive value of the three-marker assay was 87.2{\%} (+PPV) and 97{\%} (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.",
author = "Kim, {Dong Su} and Choi, {Young Deuk} and Mihyang Moon and Suki Kang and Lim, {Jong Baeck} and Kim, {Kyung Min} and Park, {Kyung Mok} and Cho, {Nam Hoon}",
year = "2013",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-12-1156",
language = "English",
volume = "22",
pages = "390--398",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

Composite three-marker assay for early detection of kidney cancer. / Kim, Dong Su; Choi, Young Deuk; Moon, Mihyang; Kang, Suki; Lim, Jong Baeck; Kim, Kyung Min; Park, Kyung Mok; Cho, Nam Hoon.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 22, No. 3, 01.03.2013, p. 390-398.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Composite three-marker assay for early detection of kidney cancer

AU - Kim, Dong Su

AU - Choi, Young Deuk

AU - Moon, Mihyang

AU - Kang, Suki

AU - Lim, Jong Baeck

AU - Kim, Kyung Min

AU - Park, Kyung Mok

AU - Cho, Nam Hoon

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.

AB - Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.

UR - http://www.scopus.com/inward/record.url?scp=84876588154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876588154&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-12-1156

DO - 10.1158/1055-9965.EPI-12-1156

M3 - Article

C2 - 23479363

AN - SCOPUS:84876588154

VL - 22

SP - 390

EP - 398

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -